Abstract. Bufadienolides are constituents of the traditional Chinese medicine Chan Su and are found in toad venom. Cardiovascular side-effects are one of the limiting factors towards developing bufadienolides as chemotherapeutic agents. Thus, in the present study, low doses of bufalin and cinobufotalin, prominent members of the bufadienolides, were investigated for their cytotoxic activity in combination with hyperthermia (HT) or radiation (Rad) therapy. In addition, the underlying mechanism involved was investigated. A DNA fragmentation assay, viability assay and microscopic observation were primarily used to assess the effect of low doses of the two drugs in human lymphoma U937 cells. Furthermore, the effects of these drugs on the mitochondrial membrane potential (MMP) and apoptotic-associated protein activation were investigated. HT/bufadienolide-and RT/bufadienolide-treated samples significantly increased the DNA fragmentation percentile and decreased the MMP, as well as increasing the apoptotic features observed microscopically within a relatively short time (6 h) after treatment. The two combinations affected the expression of important apoptotic markers, including caspase-3 and BH3 interacting domain death agonist. The findings of the current study confirm the additive effect of HT with this group of drugs, directing a novel therapeutic avenue for the clinical use of bufadienolides at lower doses with more restrained cardio toxic side-effects.
Introduction
Bufalin (B) and cinobufotalin (CB) are two members of the cardiotonic steroids known as the bufadienolides and constituents of the traditional Chinese medicine Chan Su. The drugs are also known to be found in toad venom, which is extracted from the skin secretions of giant toads, including Bufo gargarizans (1) . In a previous study, we found that CB was able to significantly induce apoptotic cell death in the human lymphoma U937 cell line at concentrations >0.5 µM (2) . In addition, B was demonstrated to significantly induce apoptotic cell death in various cancer cell types at concentrations >0.1 µM (3) (4) (5) (6) . The preferential killing of tumor cells by bufadienolides has made them potential candidates for chemotherapeutic research in the last 50 years; however, owing to their structural resemblance to digitalis glycosides, they also act as potent cardiotonic steroids, which increase the contractile force of the heart muscle. This effect is a result of the action of bufadienolides on the Na + /K + -ATPase pump, an essential membrane protein of animal cells, which results in an increase in the cytoplasmic Ca 2+ concentration (1) . The application of bufadienolides in cancer treatment is, therefore, restricted by their cardiotoxic side-effects.
Previous studies have revealed that hyperthermia (HT) and radiation (Rad) are able to enhance the cell killing effect of cytotoxic drugs, termed thermal-and radio-chemosensitization, either directly through affecting drug activity or indirectly through affecting the cancer cell itself (7) (8) (9) (10) (11) (12) . The adjuvant effect of this combination allows for the lowering of the chemotherapeutic dose required, thus lowering the unfavorable side-effects. Overall, the benefits of their concomitant use evidently overweigh the possible aforementioned disadvantages. For this reason, the scope of the present study was to investigate the possibility of lowering the chemotherapeutic dose of bufadienolides in combination with HT or Rad, while maintaining the chemotherapeutic efficacy.
Materials and methods
Drug and drug concentration. CB was purchased from Sigma-Aldrich (Merck KGgA, Darmstadt, Germany), while B was purchased from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). Stock solutions were prepared using DMSO as a solvent, and further dissolved to make the desired concentrations for experimental use. The minimum toxic doses of CB and B were then determined using DNA fragmentation and cell viability assays, and were identified as 0. respectively (data not shown). Accordingly, further experiments were conducted using these concentrations for 6-h incubation periods.
Cell culture. The human lymphoma U937 cell line, obtained from the Health Sciences Research Resource Bank (Japan Health Sciences Foundation, Tokyo, Japan) was maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; both Sigma-Aldrich; Merck KGaA). The cell line was maintained at 37˚C in a humidified atmosphere with 5% CO 2 . Cells were harvested when they reached 80% confluence and subcultures of 1x10 6 cells/ml were used in all assays.
Heat stress exposure. HT is known to cause cell membrane damage and impairment to the ion transport mechanisms (7) . Thus, treating the cells with HT prior to B and CB administration diminishes the cytotoxic activity of the drugs that principally target the Na + /K + pump. The drugs (0.2 µM CB and 0.1 µM B) were therefore administered for 1 h prior to HT treatment. Cells were transferred into test tubes and placed in a hot water bath at 44˚C for 20 min. Subsequently, the cells were transferred into plates and incubated for 6 h at 37˚C, prior to the required assay.
X-irradiation. U937 cells (1x10
6 cells/ml) were treated with B and CB in a 6-cm culture dish for 1 h at room temperature prior to Rad. X-irradiation was performed at room temperature using X-ray apparatus (MBR-1520R-3; Hitachi, Ltd., Tokyo, Japan) operating at 150 kV and 20 mA, at a dose rate of 5 Gy/min, 10 Gy total as determined using Fricke dosimetry. Cells were subsequently incubated for 6 h at 37˚C with 5% CO 2 for further assessment.
Assessment of apoptosis.
Morphological examination was performed using Giemsa staining under a light microscope (magnification, x400), and a quantitative assay of DNA fragmentation was performed according to the modified Sellins and Cohen method (13, 14) .
Assessment of cell viability. Cell viability was evaluated by WST-1 cell viability assay using a WST-1 Cell Counting kit (Dojindo Molecular Technologies Inc., Kumamoto, Japan) according to the manufacturer's protocol. Briefly, cell suspensions were subjected to drug (CB or B) treatment, HT or Rad, then equal volumes of the cell suspension were seeded into 96-well plate followed by a further incubation period for 6 h at 37˚C. Subsequently, cells were subjected to the WST-1 assay. The absorbance was measured at 450 nm using a microplate reader.
Assessment of mitochondrial membrane potential (MMP).
To measure the changes in the MMP, U937 cells were harvested by centrifugation at 350 x g at 4˚C for 4 mins and stained with 10 nM tetramethylrhodamine methyl ester (TMRM; Molecular Probes; Thermo Fisher Scientific, Inc., Waltham, MA, USA) for 15 min at 37˚C in PBS containing 1% FBS. The fluorescence of TMRM was then analyzed using flow cytometry (excitation wavelength, 488 nm; emission wavelength, 575 nm) (15) .
Western blot analysis of proteins. Western blot analysis was performed as described previously (2) . Cells were collected and washed with cold PBS, then lysed using lysis buffer for 20 min at 4˚C (1 M Tris-HCl, 5 M NaCl, 1% Nonidet P-40 (v/v), 1% sodium deoxycholate, 0.05% SDS, 1 mM phenylmethylsulfonyl fluoride). Following brief sonication, the lysates were centrifuged at 13,362 x g for 10 min at 4˚C and the protein content in the supernatant was measured using a Bio-Rad protein system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Total protein (30 µg) was heated at 96˚C for 5 min following mixing with 5 µl of SDS-loading buffer. Samples were then subjected to 12% SDS-PAGE (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan) and transferred to nitrocellulose membranes (GE Healthcare Life Sciences, Chalfont, UK). Membranes were then blocked using 1X Tris-buffered saline-Tween 20 with 5% w/v non-fat dry milk for 1 h at room temperature. Western blot analysis was performed using anti-BH3 interacting domain death agonist (Bid,), anti-caspase-3 and anti-heat shock 70-kDa protein (HSP-70; 2002S, 9661S and 4872S, respectively; Cell Signaling Technology, Inc., Danvers, MA, USA) polyclonal antibodies, and anti-β-actin monoclonal antibody (A2228, Sigma-Aldrich; Merck KGgA). The membranes and the primary antibodies (all at 1:1,000 dilution) were incubated overnight with gentle agitation at 4˚C. Following their incubation with horseradish peroxidase-conjugated anti-rabbit and anti-mouse immunoglobulin G secondary antibodies for 1 h at room temperature, band signals were visualized on X-ray film using a chemiluminescence EspspCL system (NA934 and NA931, respectively; GE Healthcare Life Sciences, Chalfont, UK) (15) .
Statistical analysis. The statistical analysis was performed using JMP software (version 10; SAS Institute, Inc., Cary, NC, USA). Data are presented as the mean ± standard deviation. Statistical significance was evaluated using one-way analysis of variance followed by the Bonferroni post hoc test. All experiments were performed in triplicate. P<0.01 was considered to indicate a statistically significant difference.
Results

Effect of combining HT or Rad on the cytotoxic activity of B and CB.
Based on our previous studies, the minimum toxic doses for B and CB in U937 cells were identified as 0.01 and 0.2 µM, respectively (2, 5, 6) . Upon further analysis, administration of B (0.1 µM) and CB (0.2 µM) in combination with HT (44˚C for 20 min) or Rad (10 Gy) was demonstrated to significantly increase the DNA fragmentation compared with single-drug treatment groups (P<0.01; Fig. 1A) . Treated cells were then examined using Giemsa staining under a light microscope. Untreated cells exhibited intact nuclear structure, whereas B and CB in combination with HT-treated cells showed typical apoptotic morphological changes, as indicated by chromosomal condensation and nuclear fragmentation (Fig. 1B) .
Decrease in cell viability. U937 cells were treated as aforementioned, followed by use of the WST-1 cell viability assay. In coherence with the previous assays, B/HT-and CB/HT-treated cells showed a significant decrease in cell viability, reaching 40.0±4.0 and 35.0±3.0%, respectively, following 6 h of incubation (Fig. 2) . Similarly, B/Rad-and CB/Rad-treated cells showed a further decrease in cell viability, reaching 20.0±4.0 and 15.0±3.0%, respectively, following 6 h of incubation (Fig. 2) .
Induction of MMP.
To assess the effect of these combinations on the MMP of U937 cells, treated cells were assessed for MMP decline using TMRM staining. The results revealed significant reductions in MMP in the combination-treatment groups compared with treatment with the drugs alone, as shown in Fig. 3 .
Ef fect on apoptosis-associated protein expression.
Caspases serve an important role in the apoptotic signaling pathway and are considered as the main executioners of cell death (16) . To examine the involvement of the caspases in the effect of HT or Rad on the two drugs, western blot analysis was performed using caspase-3 antibody following 6 h of treatment of U937 cells using the treatment combinations. Given that the activation of a specific caspase results in the reduction of its pro-enzyme form, it was demonstrated that the protein levels of procaspase-3 were markedly downregulated in the HT-or Rad-treated groups (Fig. 4) . Simultaneously, the cleaved form of caspase-3 was also markedly detectable in the groups treated in combination with HT or Rad. Expression of activated pro-apoptotic proteins, including Bid, were also demonstrated to be markedly decreased with regard to cytosolic levels, as shown in Fig. 4 . However, HSP70 expression was upregulated in the HT-treated groups. 
Discussion
Cardiac glycosides (CG) belong to the most commonly used group of drugs in medicine. The two main subgroups of CG are the cardenolides, where ouabin and its derivative digoxin are the most typical examples, and the bufadienolides, which the present study was focused upon. There are ~250 substances in the bufadienolide group, including B and CB (17) . The bufadienolides have been previously investigated in several studies for their cytotoxic activity, as well as the underlying signaling pathway involved (3) (4) (5) (6) . Bufadienolides act primarily through inhibiting the transport enzyme Na + /K + -adenosine triphosphatase (18) , thus acting as their signal transducer. Conversely, despite the cytotoxic nature of bufadienolides, a previous study reported their use in cardiovascular and kidney diseases (19) . Introducing the bufadienolides as chemotherapeutic agents also depends on the extent of their cardiovascular side-effects. However, their cell type specificity towards cancer cells and the use of specific bufadienolides at low doses and for long periods without severe side-effects have been reported (20, 21) . Thus, in the present study, the use of B and CB was investigated at the lowest cytotoxic dose in combination with HT or Rad in order to attain a significant cytotoxicity with limited possible side-effects. HT efficacy is not sufficient to replace any of the therapeutic modalities when used alone, yet it has shown significant results in enhancing the cell killing effect of other cytotoxic drugs. HT induces several changes in the cellular physiology, including at the level of the cell membrane of the cancer cell and on a nucleic acid level (7) . Generally, HT cannot cause severe damage by itself, but instead, independently hinders the repair of cell damage (22, 23) . Furthermore, HT affects the fluidity and stability of cellular membranes, and hinders the function of the transmembrane transport proteins and cell surface receptors (24) (25) (26) (27) (28) . In addition, X-irradiation is known to induce apoptosis by acting directly on the plasma membrane and nuclear DNA, or both (14) . Simultaneously, mitochondrial-dependent generation of reactive oxygen species serves an essential role in G 2 /M arrest and X-irradiation-induced apoptosis (29, 30) . Accordingly, the present study reported promising results when B and CB were administered 1 h prior to HT or Rad treatment avoiding its destructive effect on the cell membrane, which is the primary target of B and CB.
In all the assays in the current study, B was identified to be generally more cytotoxic when compared with CB, and HT significantly enhanced the cytotoxic effect of low doses of the two drugs. Notably, HT was able to potentiate the cytotoxic activity of CB to be almost equal to that of B alone. The apoptotic nature of the drugs appeared to be unhindered yet augmented. Firstly, using Giemsa staining, the presence of apoptotic-like bodies in all treatment groups was demonstrated and was more evident in the CB/HT and B/HT combinations compared with the groups with drug treatment alone. To assess the viability of the cells, a WST-1 cell viability assay was used. The results demonstrated that ~50% of the cells died within 6 h in the CB/HT and B/HT combination groups vs. 20-30% of cells when the drugs were used alone. Additionally, the DNA fragmentation assay revealed a significant increase in the DNA fragments in the combination groups. Furthermore, the effects of the combinations were greater when assessing the MMP, since there was doubling in the MMP percentile loss in the two drugs. MMP is the preliminary step towards the initiation of programmed cell death (31, 32) . This eventually leads to the activation of caspase-3, followed by DNA fragmentation and cell death (33, 34) . HT and Rad enhanced the expression of caspase-3 and Bid proteins when combined with the drugs. However, the upregulation of HSP70, acknowledged as an anti-apoptotic protein, remains a question to be assessed. Nevertheless, few previous studies have demonstrated the apoptotic nature of the HSP70 protein. This could stand as an explanation for the lack of a synergistic effect of this combination (35) .
In conclusion, HT and Rad, in combinations with low doses of B and CB appear to enhance the apoptotic cell death of U937 cells through the intrinsic apoptotic signaling pathway. Notably, when combined with CB, chemotherapeutic effects were demonstrated equivalent to the relatively more toxic B used alone. The present study has provided a direction for the introduction of B and CB into the chemotherapeutic field, ensuring similar efficacy while reducing the anticipated side-effects of high doses.
